Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

CJC-1295 with DAC: what it is studied alongside

CJC-1295 with DAC is a GHRH analogue studied in the GH-IGF-1 axis literature alongside other GHRH analogues, ghrelin-receptor secretagogues, and the GH fragment AOD9604. This page maps what the evidence places it with, a

peptides-pro Editorial

CJC-1295 with Drug Affinity Complex (DAC) is a growth hormone-releasing hormone (GHRH) analogue, listed in the peptide literature alongside sermorelin, tesamorelin, and CJC-1295 without DAC as the GHRH-analogue class of agents intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis [1]. It is also catalogued among performance-enhancing compounds marketed as "research compounds" rather than as approved therapeutics [1]. The evidence block supplied here does not give a sequence, molecular formula, or molecular weight for the molecule, so none is stated.

The work around it centres on the GHRH receptor and the somatotroph axis it drives, with the GH-IGF-1 cascade as the downstream readout [1].

For laboratory reference, the catalogue entry for this compound is CJC-1295 with DAC.

Research Studies

CJC-1295 with DAC and other GHRH analogues in the GH-IGF-1 axis literature

The clearest statement the evidence makes about what this compound is studied alongside is taxonomic. In a review of performance-enhancing peptides that modulate the GH-IGF-1 axis, CJC-1295 with DAC appears in the same functional grouping as sermorelin, tesamorelin, and CJC-1295 without DAC — all GHRH analogues — and that grouping is distinguished from a second group, the growth hormone secretagogues [1]. The review frames both groups as agents encountered in clinical practice and in online self-administration protocols, and as marketed under a research-compound label [1].

That is a statement about how the literature classifies the compound, not a finding about what it does. The evidence block does not supply comparative potency, receptor-binding, or half-life data for CJC-1295 with DAC against the other GHRH analogues, so no such comparison is made here.

CJC-1295 with DAC and growth hormone secretagogues as a paired category

The second category the evidence places alongside GHRH analogues is the growth hormone secretagogues, named there as GHRP-2, GHRP-6, hexarelin, and ipamorelin [1]. The review treats GHRH analogues and GHS as the two peptide families most commonly encountered in the GH-IGF-1 axis context [1]. A separate critical review of peptide and peptide-analogue use in sport and bodybuilding likewise groups growth hormone secretagogues such as ipamorelin as agents that have displaced anabolic-androgenic steroids in some use patterns, marketed as more selective alternatives [10].

These two families are described as co-occurring in the same discussion, not as a studied combination. The evidence block contains no co-administration study pairing CJC-1295 with DAC and any named secretagogue, and none is implied.

CJC-1295 with DAC and AOD9604 within the marketed peptide set

A third item the evidence lists in the same inventory is the GH fragment AOD9604 (hGH 176-191), which appears in the same review's enumeration of GH-IGF-1-axis agents as the GHRH analogues and secretagogues [1]. A separate review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance also names AOD-9604 among the prominent unapproved peptides marketed direct to patients [4][5].

Again, this is co-listing within a market and literature survey, not evidence of interaction. The evidence block does not report any study in which CJC-1295 with DAC and AOD9604 were administered together or compared head to head.

CJC-1295 with DAC and IGF-1 analogues in the same axis description

The GH-IGF-1 axis review extends its inventory to the insulin-like growth factor-1 analogue class, placing it in the same axis-level discussion as the GHRH analogues [1]. The axis framing is the point: GHRH analogues sit upstream, secretagogues act through a separate receptor route, and IGF-1 analogues sit downstream of GH itself [1].

The evidence block does not provide a study combining CJC-1295 with DAC and an IGF-1 analogue, and does not provide downstream IGF-1 response values for this compound. No such values are reported here.

CJC-1295 with DAC in a Phase 2 study population: HIV-associated visceral obesity

The one human interventional record in the evidence block is a multicentre, randomised, placebo-controlled, double-blind Phase 2 study of CJC 1295 in patients with HIV-associated visceral obesity [6]. Participants were treated for 12 weeks with a 6-week post-treatment follow-up, and were randomly assigned to low-dose CJC 1295, high-dose CJC 1295, or placebo [6]. The stated objective was to assess and compare efficacy, pharmacokinetics, safety, and tolerability in that population [6].

This is the population in which the compound was formally studied under trial conditions: adults with HIV and visceral obesity. The evidence block does not report the trial's results, effect sizes, or adverse-event rates, so none are stated. It also does not establish that findings in that population transfer to any other group.

CJC-1295 with DAC and purity variability in the research-peptide market

Where the compound is studied alongside market-surveillance questions rather than pharmacology, the relevant evidence is an evaluation of research-grade peptides marketed directly to consumers, which assessed purity, measured abundance, and endotoxin burden using a large publicly available independent testing dataset and compared cost against compounded and FDA-approved alternatives [2]. That study describes a rapidly expanding, largely unregulated gray market in which patients self-administer peptides for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement [2].

The finding is about the market category, not about CJC-1295 with DAC specifically. The evidence block does not report a per-compound purity figure for this molecule, and none is given.

CJC-1295 with DAC and the musculoskeletal and sports-medicine evidence base

A structured narrative review of injectable peptides in sports medicine reports that clinical adoption has outpaced high-quality evidence and regulatory consensus, summarising human and translational evidence over a defined recent window [8]. A related review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance sets out pharmacological mechanisms, safety profiles, and regulatory status for prominent peptides marketed direct to patients [4][5][9]. A further review of peptide supplements in sports medicine notes that these products are often perceived as low risk despite the absence of efficacy or safety data [7].

These sources describe the evidentiary environment around the compound class. They do not report efficacy outcomes for CJC-1295 with DAC in musculoskeletal injury or athletic performance, and no such outcome is claimed here.

CJC-1295 with DAC and the gerontological peptide literature

A narrative review of therapeutic peptides in gerontology covers mechanisms, clinical applications, evidence base, and safety profiles for peptides with demonstrated or potential applications in healthy aging and age-related conditions, targeting hallmarks that include metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline [3]. The review's scope is the peptide class as a whole.

The evidence block does not attribute any gerontological finding specifically to CJC-1295 with DAC, and none is attributed here.

Where the evidence sits

Evidence typeWhat it covers for this compoundSource
Human interventional trialPhase 2, randomised, placebo-controlled, double-blind; 12-week treatment plus 6-week follow-up; adults with HIV-associated visceral obesity; low dose, high dose, or placebo[6]
Narrative review, class-levelClassification of CJC-1295 with DAC among GHRH analogues; co-listing with secretagogues, AOD9604, and IGF-1 analogues[1]
Market surveillancePurity, measured abundance, and endotoxin burden across research-grade peptides sold direct to consumers[2]
Narrative review, gerontologyPeptide therapeutics and hallmarks of aging, class-level[3]
Narrative review, sports medicineMechanisms, safety profiles, and regulatory status of approved and unapproved peptides[4][5][7][8][9]
Critical review, dopingPeptide and peptide-analogue use in sport and bodybuilding, including growth hormone secretagogues[10]

No animal-only or in vitro study of CJC-1295 with DAC appears in the evidence block. The human record is limited to the single Phase 2 trial population described above [6]; everything else is class-level review or market-level surveillance [1][2][3][4][5][7][8][9][10].

If you are reading this for personal health reasons

This material is sold for laboratory research use only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp